Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

Summary

To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.

Timeline

Start

2010-05

Primary completion

2010-11

Completion

2010-11

Outcome

Met primary endpoint

release “BCX4208 alone and in combination with allopurinol in gout patients met its primary endpoint related to sUA reduction.” biocryst.com ↗

release “BCX4208 alone and in combination with allopurinol in gout patients met its primary endpoint” biocryst.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allopurinol	Small molecule	100 mg	—
Subject	Allopurinol	Small molecule	200 mg	—
Subject	Allopurinol	Small molecule	300 mg	—
Subject	Ulodesine	Small molecule	20 mg	—
Subject	Ulodesine	Small molecule	40 mg	—
Subject	Ulodesine	Small molecule	80 mg	—

Indications